HarrisAGelbardMDPhD

PubMed

• Hybrid Amyloid Quantum Dot Nano-Bio Assemblies to Probe Neuroinflammatory Damage.
  Wesley Chiang, Jennifer M Urban, Francine Yanchik-Slade, Angela Stout, Jennetta M Hammond
  ACS Chemical Neuroscience. 2024-09-04
• SARS and synapses.
  Harris A Gelbard, Wesley Chiang
  Nature Microbiology. 2024-05-01
• Long-term outcomes after new onset seizure in children living with HIV: A cohort study.
  Gretchen L Birbeck, Musaku Mwenechanya, Ifunanya Ume-Ezeoke, Manoj Mathews, Christopher M Bositis
  Epilepsia Open. 2024-04-01

Journal Articles

• Behavioral Deficits at 18-22 Months of Age Are Associated with Early Cerebellar Injury and Cognitive and Language Performance in Children Born Extremely Preterm  
  Duncan AF, Bann CM, Dempsey A, Peralta-Carcelen M, Hintz S, Gelbard HA, J Pediatr, 1/3/2018
• Long acting slow effective release antiretroviral therapy  
  Edagwa B, McMillan JE, Sillman B, Gendelman HE, Gelbard HA, Expert Opin Drug Deliv, 1/14/2017
• Platelet-activating factor receptors mediate excitatory post-synaptic hippocampal injury in experimental autoimmune encephalomyelitis  
  Bellizzi MJ, Geathers J, Allan K, Gelbard HA, J. Neurosci., 1/27/2016
• Planning Future Strategies for Domestic and International NeuroAIDS Research, July 24-25, 2008  
  Joseph J, Clifford D, Douglas SD, Fox H, Gendelman HE, Gonzalez-Scarano F, Grant I, Major E, McArthur J; NeuroAIDS Research Participants, J Neuroimmune Pharmacol., 1/1/2009
• Randomized Trial of the PAF Antagonist Lexipafant in HIV- Associated Cognitive Impairment  
  Schifitto G, Sacktor N, Marder K, McDermott MP, McArthur JC, Kieburtz K, Small S, Epstein LG, Palumbo D, Hickey C, Bourgeois K, Kost J, Gelbard HA, Kamp C, Schwid S, O..., Neurology, 1/1/1999
• A randomized, double- blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment  
  The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders (Kieburtz K, Schifitto G, McDermoot M, Bourgeous K, Palumbo D, Orme C, Zimmerman C, Gel..., Neurology, 1/1/1998
• Safety and tolerability of the antioxidant OPC-14117 in HIV associated cognitive impairment  
  The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders. (Marder K, Ramamchandran G, Albert S, Dooneief, G, Stern Y, Todak G, Friedman- Clouse ..., Neurology, 1/1/1997
• Clinical confirmation of the American Academy of Neurology algorithm for HIV-1 associated cognitive motor disorder  
  The Dana Consortium on Therapy for HIV Dementia and Related Cognitive Disorders (Marder K, Albert S, Dooneief G, Stern Y, Todak G, Friedman-Clouse R, Polanco C, Winsto..., Neurology, 1/1/1996
• Increased prevalence of electrophysiological abnormalities in children with psychological, physical and sexual abuse  
  Ito Y, Teicher MH, Glod CA, Harper D, Magnus E, and Gelbard, HA, J Neuropsych. and Clin. Neurosciences, 1/1/1993
• Neonatal depletion of dopamine decreases D1 and forskolin binding sites in rat striatum  
  Gelbard HA, Teicher MH, Beers NB, Gallitano A, Baldessarini RJ, Posters in Neuroscience, 1/1/1991
• Join now to see all

Books/Book Chapters

• Encyclopedia of AIDS 
  Chapter: HAND adjunctive therapies: reversing neuronal injury. 
  Marker DF, Fitzgerald, T and Gelbard HAEditors: Hope, TJ, Stevenson, M, and Richman, D.Springer Science + Business Media, New York2015
• Microglia in Health and Disease 
  Chapter: Human immunodeficiency virus. 
  Page 373 - 392Marker DF, Lu S-M and Gelbard HAEditors: Tremblay M� and Sierra A.Springer Science + Business Media, New York2014
• The Neurology of AIDS 
  Chapter: Development of Adjunctive Therapies for the Neurological Manifestations of AIDS: HAND and Painful Neuropathy. 
  Gelbard HA and Lipton SAEditors: Everall, Fox, Gelbard, Grant, Lipton, Swindells and Gendelman.Oxford Press, New YorkEdition 3rd,2012
• Encyclopedia of Neuroscience, Vol. 5 
  Chapter: Infectious Agents in Neurodegenerative Disease. 
  Page 125 - 129Bellizzi MJ and Gelbard HAEditors: Squire LR.Academic Press, Oxford2009
• The Spectrum of Neuro-AIDS Disorders: Pathophysiology, Diagnosis, and Treatment. 
  Chapter: Chapter 11: Neuroimmunology and the Pathogenesis of HIV-1 Encephalitis in the HAART Era: Implications for Neuroprotective Treatment. 
  Perry SW and Gelbard HAEditors: Goodkin, Shapshak, and Verma.ASM Press, New York2008
• Neurotox. Res., Special issue on Neurotoxicity and Neuroprotection in HIV-induced Neurological Disorders. 
  Chapter: The Plasticity-pathology continuum in neuroAIDS. 
  Gelbard HA2005
• The Neurology of AIDS 
  Chapter: Development of Adjunctive Therapies for the Neurological Manifestations of AIDS: Dementia and Painful Neuropathy. 
  Lipton SA and Gelbard HAEditors: Gendelman.Chapman and Hall, New YorkEdition 2nd,2004
• AIDS and Other Manifestations of HIV Infections 
  Chapter: The Neuropathogenesis of HIV-1 Infection. 
  Gendelman HE, Diesing S., Gelbard HA, and Swindells S.Editors: Wormser.Edition 4th,2002
• Apoptosis in Neurobiology, CRC Methods in Neurobiology 
  Chapter: HIV-1 and Apoptosis in the Nervous System. 
  Page 61 - 72Gelbard HAEditors: Boustany and Hannun.CRC Press, Boca Raton1999
• Ann. N.Y. Acad. Sci. 
  Chapter: Neuroprotective strategies for HIV-1-associated neurologic disease. 
  Page 312 - 313Gelbard HA1999
• Cell Death and Diseases of the Nervous System 
  Chapter: HIV-1 Infection of the CNS: Evidence for Apoptosis of Neural Cells. 
  Page 511 - 519Gelbard HAEditors: Ratan.Humana Press, New Jersey1998
• The Neurology of AIDS 
  Chapter: HIV-induced neurotoxicity in the developing central nervous system. 
  Page 419 - 424Gelbard HAEditors: Gendelman.Chapman and Hall, New York1998
• Textbook of Neuropsychiatry 
  Chapter: Neuropsychiatric disorders of childhood and adolescence. 
  Page 903 - 940Teicher MH, Andersen SL, Glod CA, Navalta CP, and Gelbard HAEditors: Yudofsky and Hales.Edition Thir,1997
• Severe Stress and Mental Disturbance in Children 
  Chapter: Neurophysiological mechanisms of stress response in children. 
  Page 59 - 84Teicher, MH, Ito, Y, Glod, CA, Schiffer, F, and Gelbard, HAEditors: Pfeffer.1996
• Technical Advances in AIDS Research in the Human Nervous System 
  Chapter: HIV-1- derived neurotoxic factors: effects on human neuronal cultures. 
  Page 61 - 71Gelbard, HA, Dzenko KA, Wang L, Talley A, James H, and L EpsteinEditors: Major.Plenum Press, New York1995
• New Concepts in AIDS Pathogenesis 
  Chapter: Experimental model systems for studies of HIV- associated CNS disease. 
  Page 89 - 113Gendelman HE, Genis P, Jett M, Bernton EW, Gelbard, HA, Cvetkovich TA, Lazar ES, del Cerro M, and Epstein LGEditors: Montagnier and Gougeon.Marcel Dekker1994
• Biological and Neurobehavioral Studies of Borderline Personality Disorder 
  Chapter: Early Abuse, Limbic System Dysfunction, and Borderline Personality Disorder. 
  Page 177 - 207Teicher MH, Ito Y, Glod CA, Schiffer F, and Gelbard, HAEditors: K.R. Silk.American Psychiatric Press, Inc.1994
• Psychiatry: A World Perspective Volume, Vol. II 
  Chapter: Development of the dopamine D1 receptor system depends on endogenous dopamine. 
  Page 651 - 658Gelbard, HA., Teicher, MH, Baldessarini, RJ, Gallitano, A, Marsh, ER, Zorc, J, and Faedda, GEditors: CN Stefanis, CR Soldatas, and AD Rabavilas.Elsevier Science Publishers, Amsterdam1990
• Steroid Hormone Regulations of the Brain 
  Chapter: 1 alpha, 25-(OH)2 vitamin D3 receptors in the pituitary: Characterization and relation to dopaminergic mechanisms. 
  Page 265 - 276Gelbard, HA, Stern, PH and U'Prichard, DCEditors: K. Fuxe, J-A Gustafson and L Wetterberg.Pergamon Press, Oxford1981
• Join now to see all

Lectures

• "The development of URMC-099, a broad spectrum mixed kinase inhibitor for the treatment of non-alcoholic steatohepatitis." 
  China - 1/1/2018
• "Broad spectrum inhibition of mixed lineage kinases: Roles for URMC-099 in NASH, persistent HIV-1 infection and HAND." 
  Lianyungang, China - 1/1/2018
• "Selectively non-selective inhibition of innate immunity: A role for URMC-099 in CRISPR/Cas9-based HIV-1 cure strategies." 
  Philadelphia, PA - 1/1/2018
• "Found in translation, the strange but true story of how URMC-099 came to be." 
  Chicago, IL - 1/1/2017
• "Inhibition of innate immunity: a therapeutic strategy for Zika virus infection." 
  Los Angeles, CA - 1/1/2017
• "Selectively non- selective inhibition of innate immunity: Treatment for end organ diseases of infectious and non-infectious etiologies." 
  Drexel University, Philadelphia, PA - 1/1/2016
• "Inhibition of Mixed Lineage Kinases as a Disease Modifying Strategy for HAND: An Unusally Narrow Path for Patents." 
  San Diego, CA - 1/1/2015
• "Adventures in the Small World: A Novel Approach to Understanding Intracellular Events During HIV-1 Infection of the CNS." 
  1/1/2015
• "Why cART has failed to change the prevalence of HAND � Mechanisms and strategies for adjunctive therapies." 
  1/1/2014
• "Why inhibition of mixed lineage kinases matters for HIV-1 and HAND." 
  1/1/2014
• "MLK3 Inhibition: A Disease-Modifying Strategy for HAND." 
  NIH, Bethesda, MD - 1/19/2012
• "Modeling HIV-1 Associated Neurocognitive Disorders: The Need for the Incredible Shrinking Model" 
  University of Rochester - 1/23/2011
• "Got Memory? Neuroinflammation and Cognitive Dysfunction in Chronic Disease and Aging" 
  URMC - 1/8/2010
• "The Brain that Changes Itself in a Model of NeuroAIDS" 
  1/8/2010
• "Development of Centrally Acting Novel Kinase Inhibitors for NeuroAIDS" 
  Cold Spring Harbor - 1/8/2010
• "HIV-1 and HAND in the time of cART or Dr. Strangelove's take on science is what happens while you're making plans." 
  1/1/2010
• "Enduring NeuroImmune Events that Lead to HAND (HIV-1 Associated Neurocognitive Disorders)." 
  Wuhan, China - 1/21/2009
• "Wash your HANDS(s) After Swimming in the Meme Pool." 
  1/17/2009
• "Neuroprotective Strategies for HIV-1." 
  University of Rochester Medical Center - 1/15/2009
• "HIV-1 and the Developing Brain in the Era of cART." 
  1/8/2009
• "Potential NeuroAIDS Therapeutic Targets Emerging from Neuroscience/Neuroimmunology." 
  Washington, DC - 1/5/2009
• "Why is mixed lineage kinase activity so important for drug development in NeuroAIDS." 
  Miami, FL - 1/2/2009
• "Strategic Planning Meeting for Domestic and International NeuroAIDS Research" 
  Bethesda, MD - 1/24/2008
• Symposium in the areas of Neuropathogenesis and Vaccine Development in honor of the late Opendra "Bill" Narayan (1936-2007) 
  1/23/2008
• "Modeling NeuroAIDS � From Molecular Targets to Hit-to-Lead Compound Discovery." 
  Bethesda, MD - 1/30/2007
• Join now to see all

Other

• Multi-target drugs should be in the pharma pipeline along with precision drugs. 
  Harris A. Gelbard, Statnews
  1/31/2019
• Mixed Lineage Kinase Inhibitors for HIV/AIDS Therapies. 
  HA Gelbard, S Dewhurst and H Gendelman, China Patent #ZL201380060736.1.
  1/10/2018
• Mixed Lineage Kinase Inhibitors and Method of Treatments. 
  VS Goodfellow, T Nguyen, SB Ravula and HA Gelbard, United States Patent #9,370,515
  1/21/2016
• MLK Inhibitors and Methods of Use. 
  H Gelbard, S Dewhurst, VS Goodfellow, CJ Loweth, and T Wiemann, New Zealand Patent #614904
  1/30/2015
• Bicyclic Heteroaryl Kinase Inhibitors and Methods of Use. 
  HA Gelbard, S Dewhurst, VS Goodfellow, T Wiemann, SB Ravula and CJ Loweth, United States Patent #8,846,909
  1/30/2014
• Substituted Pyrrolo [2,3-B] Pyridines as MLK Inhibitors. 
  HA Gelbard, S Dewhurst, VS Goodfellow, CJ Loweth, and T Wiemann, United States Patent #8,877,772
  1/4/2014
• Characterization and regulation of nuclear calcitriol receptors in pituitary and neural tissues. (Doctoral Thesis) 
  Gerlbard HA, University Microfilms, Northwestern University
  1/1/1983
• Dopamine receptor heterogeneity: Neurobiological and psychopharmacological implications. 
  Teicher, MH, Gallitano, A, and Gelbard, HA, Advances in Clinical Psychopharmacology and Behavioral Neurology
• Join now to see all